These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25023354)

  • 1. Platelets, cyclooxygenases, and colon cancer.
    Guillem-Llobat P; Dovizio M; Alberti S; Bruno A; Patrignani P
    Semin Oncol; 2014 Jun; 41(3):385-96. PubMed ID: 25023354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of platelets in inflammation and cancer: novel therapeutic strategies.
    Dovizio M; Alberti S; Guillem-Llobat P; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):118-27. PubMed ID: 24118902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting.
    Mattiello T; Guerriero R; Lotti LV; Trifirò E; Felli MP; Barbarulo A; Pucci B; Gazzaniga P; Gaudio C; Frati L; Pulcinelli FM
    J Am Coll Cardiol; 2011 Aug; 58(7):752-61. PubMed ID: 21816313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
    Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
    Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulatory influence of sodium 2-propenyl thiosulfate from garlic on cyclooxygenase activity in canine platelets: possible mechanism for the anti-aggregatory effect.
    Chang HS; Yamato O; Yamasaki M; Maede Y
    Prostaglandins Leukot Essent Fatty Acids; 2005 May; 72(5):351-5. PubMed ID: 15850716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back.
    Patrono C
    Trends Pharmacol Sci; 1989 Nov; 10(11):453-8. PubMed ID: 2514478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: aspirin resistance--fact or fashion?
    Patrono C; Rocca B
    Nat Clin Pract Cardiovasc Med; 2007 Jan; 4(1):42-50. PubMed ID: 17180149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin resistance and platelet turnover: a 25-year old issue.
    Di Minno G
    Nutr Metab Cardiovasc Dis; 2011 Aug; 21(8):542-5. PubMed ID: 21745731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mode of action of aspirin as a chemopreventive agent.
    Dovizio M; Bruno A; Tacconelli S; Patrignani P
    Recent Results Cancer Res; 2013; 191():39-65. PubMed ID: 22893199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.
    Wu KK
    Semin Vasc Med; 2003 May; 3(2):107-12. PubMed ID: 15199473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
    Patrignani P; Sciulli MG; Manarini S; Santini G; Cerletti C; Evangelista V
    J Physiol Pharmacol; 1999 Dec; 50(4):661-7. PubMed ID: 10639016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioactive lipid metabolism in platelet "first responder" and cancer biology.
    Kanikarla-Marie P; Kopetz S; Hawk ET; Millward SW; Sood AK; Gresele P; Overman M; Honn K; Menter DG
    Cancer Metastasis Rev; 2018 Sep; 37(2-3):439-454. PubMed ID: 30112590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk.
    Dovizio M; Alberti S; Sacco A; Guillem-Llobat P; Schiavone S; Maier TJ; Steinhilber D; Patrignani P
    Biochem Soc Trans; 2015 Aug; 43(4):707-14. PubMed ID: 26551717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
    Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
    Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a better aspirin.
    Vane J
    Nature; 1994 Jan; 367(6460):215-6. PubMed ID: 8121485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.